NEW YORK, January 1, 2026, 20:51 ET — Market closed
- Pfizer shares last traded at $24.90, down 0.4% from the previous close.
- A Reuters report said Pfizer plans list-price increases on around 80 medicines for 2026, including a 15% hike for its COVID-19 vaccine.
- Investors are watching for more early-January pricing disclosures, the Jan. 9 U.S. jobs report and Pfizer’s expected Feb. 3 earnings date.
Pfizer Inc (PFE) shares last traded at $24.90, down 0.4% from the previous close, with U.S. markets closed on Thursday for the New Year’s Day holiday. Reuters reported Pfizer is leading a new round of U.S. list-price increases for 2026, planning hikes on around 80 drugs and vaccines — including a 15% rise for its COVID-19 shot Comirnaty — as drugmakers overall line up price increases on at least 350 branded medicines, with a median hike of about 4%. “They really just nibble around the margins,” said Dr. Benjamin Rome, a health policy researcher at Brigham and Women’s Hospital, while Pfizer said its average increase for innovative medicines and vaccines would be below inflation. Reuters
The pricing debate is hitting as Medicare’s first negotiated drug prices are set to take effect on Jan. 1, sharpening attention on how manufacturers set and defend U.S. pricing. For investors, drug pricing is a recurring risk factor because it can influence demand and trigger policy responses that shape profitability.
A list price is the published starting point before discounts. Many employers and insurers use pharmacy benefit managers, or PBMs — firms that run prescription benefits and negotiate with drugmakers — to secure rebates and set which drugs get preferred coverage, so the net price paid can differ sharply from the sticker price.
For Pfizer shareholders, the key question is how much of any sticker-price reset flows through to net sales once rebates, insurance coverage and demand shifts are factored in. The company has been working to rebuild growth beyond its pandemic-era products, where demand has faded.
In the last session, Pfizer traded between $24.88 and $25.19 on volume of about 29.4 million shares, leaving the stock near the $25 mark into the first full trading day of 2026. The move was modest, keeping the focus on headlines rather than technical momentum.
Before the next session, investors will look for any additional early-January pricing updates across the sector and for signs of a policy response from Washington. Even when list-price moves do not reflect net pricing, they can still shift sentiment because they are easy targets for political criticism.
Macro data is also looming. The U.S. employment report for December is due on Jan. 9 and the Consumer Price Index for December is scheduled for Jan. 13, according to the Labor Department’s release calendar, events that can move rates expectations and market risk appetite.
Earnings are the next scheduled company checkpoint. Pfizer is expected to report results on Feb. 3, according to Yahoo Finance’s earnings calendar, with investors focused on 2026 guidance and any commentary on net pricing and demand trends across major franchises.
Income investors also have a nearer date circled. Pfizer’s board declared a $0.43 first-quarter dividend, payable March 6 to shareholders of record as of Jan. 23, the company said.
Policy risk remains a swing factor for large-cap drugmakers. Price increases are often criticized because they can lift out-of-pocket costs for some patients, while manufacturers argue rebates and discounting mean net prices rise more slowly than list prices suggest.
On the chart, the $24.88 session low and the $25.19 high stand out as near-term reference points after the holiday break. A move outside that band would give traders an early read on direction as liquidity returns.
For now, Pfizer shares are starting 2026 with drug pricing back in the headlines and the next hard catalyst still weeks away. Investors are weighing that backdrop against the company’s broader push to sustain growth outside its COVID-era portfolio.
